October 11, 2021
Dystonias are a group of chronic movement–disabling disorders for which highly effective oral medications or disease-modifying therapies are lacking. The availability of an oral drug with disease-modifying potential would transform the current treatment landscape. 2015 Harrington Scholar-Innovator Nicole Calakos, MD, PhD, presents her study that provides strong preclinical support to further consider and develop this class of drugs for dystonia.
“I’d like to extend my appreciation to the Harrington Discovery Institute for getting me up to speed and capable in the drug discovery realm. Work that began with critical funding from Harrington Discover Institute was published recently in Science Translational Medicine.”
- Nicole Calakos, MD, PhD